S

Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250

Watchlist Manager
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
Watchlist
Price: 104 000 KRW -0.76% Market Closed
Market Cap: 2.4T KRW
Have any thoughts about
Sam Chun Dang Pharm Co Ltd?
Write Note

Sam Chun Dang Pharm Co Ltd
Pre-Tax Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Sam Chun Dang Pharm Co Ltd
Pre-Tax Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Pre-Tax Income CAGR 3Y CAGR 5Y CAGR 10Y
S
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
Pre-Tax Income
â‚©11.9B
CAGR 3-Years
N/A
CAGR 5-Years
-9%
CAGR 10-Years
-2%
Yuhan Corp
KRX:000100
Pre-Tax Income
â‚©169.6B
CAGR 3-Years
8%
CAGR 5-Years
21%
CAGR 10-Years
4%
SK Biopharmaceuticals Co Ltd
KRX:326030
Pre-Tax Income
-â‚©43.9B
CAGR 3-Years
43%
CAGR 5-Years
20%
CAGR 10-Years
N/A
Hanmi Science Co Ltd
KRX:008930
Pre-Tax Income
â‚©121.7B
CAGR 3-Years
26%
CAGR 5-Years
44%
CAGR 10-Years
18%
Hanmi Pharm Co Ltd
KRX:128940
Pre-Tax Income
â‚©226.1B
CAGR 3-Years
29%
CAGR 5-Years
30%
CAGR 10-Years
21%
C
Celltrion Pharm Inc
KOSDAQ:068760
Pre-Tax Income
â‚©22.4B
CAGR 3-Years
-19%
CAGR 5-Years
39%
CAGR 10-Years
18%
No Stocks Found

Sam Chun Dang Pharm Co Ltd
Glance View

Market Cap
2.4T KRW
Industry
Pharmaceuticals

SAM CHUN DANG PHARM Co., Ltd. engages in the manufacture of pharmaceuticals. The company is headquartered in Hwaseong, Gyeonggi-Do. The company went IPO on 2000-10-04. CO., LTD is a Korea-based company mainly engaged in the manufacture of prescription medicines. The Company’s products portfolio consists of antibiotics used for treatment of sepsis, respiratory diseases and others; circulatory disease medicines including cardiovascular and endocrine medicaments used for treatment of diabetes, hypertension, angina and others under the brand names of Glilazide and Atenolol; digestive medicines used for treatment of duodenal ulcer, gastritis and others; ophthalmological agents used for treatment of conjunctivitis, keratitis and other eye inflammation under the brand names of Ofus and Toracin, and anti-inflammatories used to release postoperative pains under the brand name Barotase and others.

Intrinsic Value
11 241.66 KRW
Overvaluation 89%
Intrinsic Value
Price
S

See Also

What is Sam Chun Dang Pharm Co Ltd's Pre-Tax Income?
Pre-Tax Income
11.9B KRW

Based on the financial report for Sep 30, 2024, Sam Chun Dang Pharm Co Ltd's Pre-Tax Income amounts to 11.9B KRW.

What is Sam Chun Dang Pharm Co Ltd's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 10Y
-2%

Back to Top